Clinical trial: predictive factors for response to gut‐directed hypnotherapy for refractory irritable bowel syndrome, a post hoc analysis
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.17790 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2024. Written by Jade Devenney and 4 co-authors. Institution: Neurogastroenterology Unit, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK. Major MEDLINE topics: Irritable Bowel Syndrome, Hypnosis. Cited 16 times so far (Crossref); 58 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIHR - Research for Patient Benefit Programme.
Abstract (original language)
Background
Gut‐directed hypnotherapy is effective for patients with irritable bowel syndrome (IBS). Despite its considerable evidence base, gut‐directed hypnotherapy is not widely available and remains a limited resource. This emphasises the need to select patients who are most likely to benefit.
Aim
To determine whether baseline patient characteristics were predictive of response to gut‐directed hypnotherapy in patients with IBS Methods We conducted a secondary analysis of outcomes of 448 patients with refractory Rome III IBS who participated in a randomised study confirming non‐inferiority of 6 compared to 12 sessions of gut‐directed hypnotherapy. We compared baseline patient characteristics, including age, sex, IBS subtype, quality of life and IBS‐Symptom Severity Scale (IBS‐SSS), non‐colonic symptom score and Hospital Anxiety and Depression (HAD) score between responders and non‐responders. We defined response as ≥50‐point decrease in IBS‐SSS or ≥30% reduction in pain severity scores.
Results
Overall, 76.3% achieved ≥50‐point decrease in IBS‐SSS. Responders had a higher baseline non‐colonic symptom score ( p = 0.005). Those who achieved ≥30% improvement in abdominal pain scores (59.8%) had higher baseline IBS‐SSS ( p = 0.03), and lower baseline HAD‐depression score ( p = 0.012). Fifty‐four patients (12%) dropped out of gut‐directed hypnotherapy. Compared to completers, dropouts had higher baseline HAD‐anxiety score ( p = 0.034).
Conclusions
These data suggest that patients with a higher burden of gastrointestinal and extraintestinal symptoms are most likely to benefit from gut‐specific behavioural intervention for refractory IBS. Clinical assessment of gastrointestinal, somatic and psychological symptom profiles may play a role in selecting patients for gut‐directed hypnotherapy.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Neurogastroenterology Unit, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
- Division of Diabetes, Endocrinology and Gastroenterology, University of Manchester, Manchester, UK.
ORCID profiles: Dipesh H Vasant
Funding
- NIHR - Research for Patient Benefit Programme
Cite
APA
Devenney, J., Hasan, S. S., Morris, J., Whorwell, P. J., & Vasant, D. H. (2024). Clinical trial: predictive factors for response to gut‐directed hypnotherapy for refractory irritable bowel syndrome, a post hoc analysis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17790
Vancouver
Devenney J, Hasan SS, Morris J, Whorwell PJ, Vasant DH. Clinical trial: predictive factors for response to gut‐directed hypnotherapy for refractory irritable bowel syndrome, a post hoc analysis. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17790
BibTeX
@article{Devenney2024,
author = {Devenney, Jade and Hasan, Syed S and Morris, Julie and Whorwell, Peter J and Vasant, Dipesh H},
title = {Clinical trial: predictive factors for response to gut‐directed hypnotherapy for refractory irritable bowel syndrome, a post hoc analysis},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.17790}
}
EUVIMED